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Abstract
Mycoplasma pneumoniae produces an ADP-ribosylating and vacuolating toxin known as the CARDS (Community Acquired
Respiratory Distress Syndrome) toxin that has been shown to be cytotoxic to mammalian cells in tissue and organ culture. In
this study we tested the ability of recombinant CARDS (rCARDS) toxin to elicit changes within the pulmonary compartment
in both mice and baboons. Animals responded to a respiratory exposure to rCARDS toxin in a dose and activity-dependent
manner by increasing the expression of the pro-inflammatory cytokines IL-1a,1 b, 6, 12, 17, TNF-a and IFN-c. There was also
a dose-dependent increase in several growth factors and chemokines following toxin exposure including KC, IL-8, RANTES,
and G-CSF. Increased expression of IFN-c was observed only in the baboon; otherwise, mice and baboons responded to
CARDS toxin in a very similar manner. Introduction of rCARDS toxin to the airways of mice or baboons resulted in a cellular
inflammatory response characterized by a dose-dependent early vacuolization and cytotoxicity of the bronchiolar
epithelium followed by a robust peribronchial and perivascular lymphocytic infiltration. In mice, rCARDS toxin caused airway
hyper-reactivity two days after toxin exposure as well as prolonged airway obstruction. The changes in airway function,
cytokine expression, and cellular inflammation correlate temporally and are consistent with what has been reported for M.
pneumoniae infection. Altogether, these data suggest that the CARDS toxin interacts extensively with the pulmonary
compartment and that the CARDS toxin is sufficient to cause prolonged inflammatory responses and airway dysfunction.
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Introduction
Mycoplasma pneumoniae is a human pathogen that preferentially
infects the respiratory tract causing acute and chronic pulmonary
disease [1,2]. Recent data suggests M. pneumoniae is responsible for
20–40% of all community acquired pneumonia, is frequently
linked to upper respiratory infections leading to tracheobronchitis
and pharyngitis, and is implicated in airway dysfunction, including
asthma [3]. However, an accurate estimate of the extent of M.
pneumoniae infection in the general population is lacking, and
infection is probably more extensive than currently accepted due
to difficulties in culturing the organism from clinical samples and
unreliable diagnostic laboratory tests [4]. Primary M. pneumoniae
infection can persist for weeks, and data from both humans and
animal models of disease suggest that M. pneumoniae infection
exacerbates chronic respiratory diseases, such as asthma and
chronic obstructive pulmonary disease (COPD) [3,5,6,7,8]. As
many as 20–30% of asthma exacerbations have been linked to
M. pneumoniae infection [5,6,7,8].
Outside of the respiratory tract, M. pneumoniae infections have
been associated with pathologies of the central nervous system,
cardiovascular system, kidneys, pancreas, liver, skin, and hema-
topoietic compartments [3]. In rare cases, fulminate disease with
fatal outcomes is possible (manuscript in preparation).
Pulmonary infection of mice with M. pneumoniae leads to a robust
inflammatory response characterized by increases in pro-inflam-
matory cytokines and chemokines, lobular pneumonia, as well as
perivascular and peribronchiolar lymphocytic infiltrates
[9,10,11,12,13,14,15,16]. We and others have reported that in
mouse models of M. pneumoniae-mediated disease these acute
inflammatory responses can persist in various forms for at least 35
days [11,12]. Besides acute inflammatory reactions, chronic
inflammatory responses can be observed in animal models of
infection. For example, in animals that are sensitized to ova
albumin and infected with M. pneumoniae, airway remodeling can
be observed suggesting that M. pneumoniae mediated inflammatory
responses are capable of causing long-term lung damage [10].
Recent studies have shown that Toll-like receptors 1, 2, and 6 are
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pneumoniae lipoproteins, leading to the activation of NF-kB and the
production of mucin in airway cells [17,18,19,20,21,22]. The
extent of Toll-like receptor-mediated inflammation in response to
M. pneumoniae infection is currently unknown, as is the full
repertoire of immune-stimulatory antigens produced by this
pathogen.
Mycoplasma pneumoniae is an atypical bacterium that lacks a cell
wall, has one of the smallest genomes known, requires a range of
host-derived nutritional components, and uses the UGA codon to
encode tryptophan [23]. Despite its limited genome, M. pneumoniae
possesses numerous virulence-related genes, specifically linked to
cytadherence and colonization [23,24,25,26]. However, unlike
many bacterial pathogens, M. pneumoniae lacks numerous classical
virulence determinants, such as specialized virulence-associated
secretion systems (type three/four) and their associated secreted
virulence products. Recently, Kannan and Baseman reported the
identification and initial characterization of the first M. pneumoniae
toxin termed the CARDS toxin (MPN372) [27,28].
The CARDS toxin is an ADP-ribosylating and vacuolating toxin
with homology to the S1 subunit of pertussis toxin that has a high
affinity for surfactant protein-A, suggesting a physiological role for
the toxin in the pulmonary compartment [27,28]. Recombinant
CARDS toxin displays a dose-dependent cytotoxic effect on both
tissue culture cells and baboon tracheal epithelium, consistent with
whatisobservedduringM. pneumoniaeinfection [27]. Not surprisingly,
the cytotoxic effect of CARDS toxin is dependent on the enzymatic
activity of the toxin because heat-inactivated (HI) toxin has no effect
on mammalian cells or tissues in culture [27]. A number of bacterial
pathogens produce ADP-ribosylating or vacuolating toxins that
contribute to the pathogenesis of diseases through the induction of
inflammation, but the CARDS toxin is the first example of a toxin
that exhibits both ADP-ribosylating and vacuolating properties
[27,29]. Until now, it was unknown if the CARDS toxin directly
impacted on the pathogenesis of M. pneumoniae infection or the extent
of host inflammatory responsiveness.
Here we report that rCARDS toxin is a potent inducer of
pulmonary inflammation in mice and baboons. rCARDS toxin-
mediated inflammatory responses are characterized by the rapid
expression of cytokines and chemokines with the concurrent
development of lymphocytic inflammation. Further, significant
increases in both airway obstruction and airway hyper-reactivity
correlate with toxin-induced inflammation. Inflammatory respons-
es and changes in airway physiology elicited by rCARDS toxin are
similar to those observed during M. pneumoniae infection suggesting
that the CARDS toxin plays a major role in the pathogenesis of
M. pneumoniae-mediated disease.
Methods
Bacteria
M. pneumoniae clinical isolate S1 was grown in SP4 liquid media
in 175 cm tissue culture flasks and quantified as previously
described [27]. Prior to infection of mice, suspensions containing
mycoplasmas were passed through 28 gauge needles to disperse
aggregates. These suspensions were used immediately to infect
mice.
Recombinant CARDS toxin: rCARDS toxin was produced and
purified to homogeneity as we have previously described [27].
Recombinant toxin preparations were maintained in carrier fluid
consisting of 50 mM Tris pH 7.4, 5% glycerol, all certified to be
low endotoxin. All toxin preparations were determined to be low
in endotoxin by Limulus assay (Lonza) and bio-assay. Preparations
of toxin used in this study contained less than 1 eu endotoxin/mg
protein as determined in the Limulus assay. Bio-activity of the
toxin was determined by the toxin’s ability to induce vacuolization
in HeLa cells as described [27].
Animals
(i) Mice. Five to ten week old female BALB/cJ mice were
purchased from Jackson Laboratory (Bar Harbor ME). Animals were
kept in an ALAC approved facility in isolator cages with free access to
food and water at all times. Depending on the experimental protocol,
mice were anesthetized either by inhalation of Isoflurane or by
intraperitoneal injection of 0.5 ml of Avertin (2,2,2-tribromoethanol;
20 mg/ml in PBS; Sigma, St. Louis, MO). Mice were then either
infected intranasally(IN) with 10
7 CFU of M. pneumoniae ortreatedIN
with the indicated molar amount of rCARDS toxin or HI toxin. The
latter was prepared by boiling toxin for one hr. Solutions of
rCARDS toxin or suspensions of M. pneumoniae were delivered in
a total volume of 30 ml applied in 15 ml/nare. Depending on
experimental needs, mice were euthanized with either an overdose of
Isoflurane (Iso-Thesia; Vetus Animal Health, Burns Veterinary
Supply, Inc., Westbury, NY) or an intraperitoneal injection of
75 mg/kg ketamine and 5 mg/kg acepromazine followed by cardiac
puncture at 0, 2, 4, 6, 14 and 37 days after toxin treatment. All
experiments were performed in accordance with Institutional
Biosafety Committee and Institutional Animal Use and Care
Committee protocols established at The University of Texas Health
Sciences Center at San Antonio and University of Texas
Southwestern Medical School.
(ii) Baboons. Two adult female baboons (Papio sp.)w e r e
housed at the Southwest Foundation for Biomedical Research
(SWFBR) in San Antonio, TX. Baboons were treated in accordance
with guidelinesestablished intheWeatherallreport‘‘The use of non-
human primates inresearch’’.Animalswere grouphoused until used
in experiments and had free access to food, water, and toys and were
monitored during study by the veterinary staff. Baboons received
ketamine sedation prior to handling for experimental procedures
and were euthanized by phenobarbital overdose. All experiments
were performed in accordance with Institutional Biosafety
Committee and Institutional Animal Use and Care Committee
protocols established at The Southwest Foundation for Biomedical
Research.
Cell culture
HeLa cells were cultured in DMEM medium supplemented
with 10% heat inactivated fetal bovine serum. Cells were
maintained in a 37uC humidified incubator with air and 5%
CO2 and used at 60–75% confluence.
Bronchoalveolar lavage (BAL)
(i) Mouse bronchoalveolar lavage fluid (BALF). To obtain
BALF, mice were euthanized, and a 1-cm longitudinal incision
was made to expose the trachea. Bronchoalveolar lavage was
performed by catheterizing the trachea using 18-gauge Angiocaths
(Becton-Dickinson Infusion Therapy Systems, Inc., Sandy, UT) as
we have described in detail before [30]. Each mouse was lavaged
with a single pass of 1-ml of PBS with protease inhibitors
(pepstatin, phenylmethylsulfonyl fluoride, aprotinin, and leupeptin
[Sigma, St. Louis, MO]). BALF samples were placed immediately
on ice, filtered with 0.2-mm syringe filters (SFCA;Fisher Scientific,
Pittsburg, PA), and stored at 280uC for future analysis. Results
reported here are representative of at least two independent
experiments performed with 5–10 animals per treatment group
and time.
(ii) Baboon BALF. Baboons were sedated prior to oral
intubation and bronchoscopy using an Olympus bronchoscope.
CARDS Tox Induced Inflammation
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of BALF. Following acquisition of baseline BALF specimens from
the left lower lobe, one animal received 700 pmol of rCARDS
toxin in carrier fluid in the right lower lobe (RLL) bronchus, and
the control baboon received the same amount of HI rCARDS
toxin in the RLL. Thereafter, BALF specimens were obtained on
days one and two from both lower lobes and frozen at 280uC for
future analysis.
Cytokine analysis
(i) Luminex analysis. BALF samples from each treatment
group were assayed to determine the presence of 21 different
mouse cytokines and chemokines using a Bio-Rad mouse array for
21 analytes as recommended by the manufacturer. Baboon
cytokine and chemokine levels were analyzed by Luminex assay
for the expression of 21 different cytokines and chemokines using a
validated primate panel developed at the Southwest Foundation
for Biomedical Research (SWFBR) and performed by the
Department of Immunology Core Facility at the SWFBR
[31,32,33]. Five to ten mouse samples per treatment group per
time point were assayed, and baboon samples were analyzed in
duplicate from each lobe.
(ii) ELISA. Enzyme-linked immunosorbent assays (ELISA)
was used to determine the concentration of select mouse cytokines.
All other cytokine measurements were done by Luminex assay.
Samples were diluted as appropriate and used in ELISA for TNF-a,
KC, MCP-1, and IL-6, (R&D Systems, Minneapolis, MN or BD
Pharmingen). BALF samples (5 to10) per timepoint were evaluated,
and each sample was assayed in triplicate. Each experiment was
done at least twice, and representative data are presented.
Histopathology
Following intranasal instillation of rCARDS toxin (43.7, 175, or
700 pmol), mouse lungs were harvested at different times, and the
gross appearance of each lobe was evaluated at necropsy. Tissue
samples were obtained at 1, 4, 7, 14, and 37 days post inoculation.
The right or left lung was fixed intrabronchially with 10% neutral
buffered formalin solution. Tissue blocks were processed and
embedded in paraffin, from which 4 um sections were cut and
stained with hematoxylin and eosin. The histopathological findings
and the grading of the lesions were done by a pathologist (JJC)
who was blinded to the experimental treatment of the animals
from which specimens were derived. Because the number of blocks
was variable from each lung, the lesions were graded as normal,
mild, moderate and severe. A severe designation was assigned
when diffuse lesions of peribronchiolar and bronchial infiltrates
and pneumonia were seen in over 50% of the lung lobe fragments;
a moderate designation was used when focal lesions of peribron-
chiolar and bronchial infiltrates and/or pneumonia were present
in 25 to 50% of the lung; and a mild designation was assigned to
the presence of a single pneumonia site in one lobe piece or several
localized lymphoid lesions in less than 25% of the lung. The
counting technique used to grade cellular lesions was the method
of Cimolai, et al [34], which was modified due to the variable lung
surface available for analysis. Images were captured digitally with
a Zeiss Axioscope 2 microscope equipped with a digital camera
and processed using the Axiovision V.4 software suite (Carl Zeiss,
Inc., Thornwood,NY).
Airway function
Changes in mouse airway function after toxin exposure were
determined by unrestrained whole-body non-sedated plethysmog-
raphy as we have previously published [11,12,13,14,15,16].
Animals were treated with various concentrations of toxin or
carrier fluid, and baseline airway obstruction (AO) was determined
by measuring the enhanced pause (Penh), a dimensionless value
representing the ratio of peak expiratory flow to peak inspiratory
flow and a function of the timing of expiration. Penh correlates with
pulmonary airway obstruction and hyperreactivity, which has
been previously validated in animal models of airway hyperreac-
tivity (AHR) [35,36,37,38]. AHR was measured after aerosolized
methacholine (100 mg/ml) challenge. Mice were serially analyzed
for AO and AHR by plethysmography on days 2, 4, 7, 14, 21, 28
and 37 days.
Statistical analysis
All results were expressed as the mean +/2 standard deviation.
Statistical differences were determined using a two-tailed Student
t-test, a Mann-Whitney U test, or Kruskal-Wallis ANOVA on
Ranks followed by Dunn’s Method with GraphPad In-Stat3
(GraphPad Software). A P value of ,0.05 was considered
significant.
Results
CARDS toxin properties
Previously, we reported that rCARDS toxin induces vacuoles in
mammalian cell lines and ADP-ribosylates host target proteins
[27]. To confirm the ability of each recombinant preparation of
CARDS toxin to elicit responses in human cells, individual lots of
toxin were tested for the ability to induce vacuoles in HeLa cells
(Figure 1). Purified rCARDS toxin appears as a single species of
68 kDa when separated by SDS-PAGE and visualized by
Coomassie blue staining confirming the purity of the toxin
(Figure 1A). Passage of rCARDS toxin through the polymixin
columns, which was used to reduce endotoxin levels, had no effect
(Figure 1A). Since this toxin was used for in vivo studies, we
measured contamination with endotoxin or other immune-
stimulatory molecules by Limulus assay and bioassay. Both active
and HI toxins have less than 1 eu of endotoxin/mg protein as
determined by Limulus assay (not shown). HeLa cells treated with
175 or 700 pmol of active CARDS toxin for 16 hrs. develop
vacuoles in a dose dependent manner in contrast to HI toxin used
as a control in these studies (Figure 1B–D). Altogether these data
suggest that the rCARDS toxin preparation used in these studies is
biologically active based on the ability to produce vacuoles in
epithelial cells. Further, Limulus assays indicate that this toxin has
very low quantities of endotoxin.
Pulmonary cytokine response to rCARDS toxin
Using mouse models of M. pneumoniae pulmonary infection, we
and others have demonstrated that the acute phase of infection is
characterized by an increase in cytokine secretion into the BALF.
In order to test the ability of rCARDS toxin to induce an immune
response in the lung, we treated mice intranasally (IN) with a single
dose of 175 or 700 pmol active rCARDS toxin, concentrations
that elicited vacuolization (Figure 1). Control animals were treated
with an equivalent dose of HI toxin. Overtly, mice exhibited no
adverse response to toxin treatment; the animals remained active;
the fur was not ruffled; and all animals survived until experimental
end-points. Then, animals were euthanized and BALF collected
for cytokine analysis on days 2, 4, 7, and 14-post toxin exposure.
Cytokine concentrations in the BALF were determined using
ELISA or Luminex assays as we have previously described
[14,15,30,39]. Specifically, ELISA was used to determine the
concentrations of IL-6, TNF-a, MCP-1, and KC on days 0, 2, and
4 post-toxin treatment, and Luminex was used to determine the
concentrations of IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9,
CARDS Tox Induced Inflammation
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7562IL-10, IL-12p40, IL-12p70, IL-13, IL-17, Eotaxin, G-CSF, GM-
CSF, IFN-c, KC, MIP-1a, MIP-1b, RANTES, TNF-a, and
PDGF on days 0, 2, 4, 7, and 14. There were no significant
differences in the concentrations of IL-2, IL-3, IL-4, IL-5, IL-9,
IL-10, IL-13, Eotaxin, GM-CSF, IFN-c, or PDGF when BALF
from active toxin and HI control mice were compared (not
shown). However, active toxin-treated mice showed a dose-
dependent cytokine response, with the most robust responses
observed in animals exposed to 700 pmol rCARDS when
compared to animals treated with 175-pmol toxin. Cytokine
responses peaked on day 2 post-exposure and declined thereafter
with most cytokine levels returning to baseline by day 4 post-
exposure. As shown in Figure 2 and Table 1, the response was
predominantly a pro-inflammatory T-helper type 1 response with
statistically significant (p,0.05) increases in the concentrations of
IL-1a and b, IL-6, 12, 17, and TNF-a ranging from 2 to 166 fold
over baseline. In addition to increases in pro-inflammatory
cytokines, there were 6 to 84 fold increases in growth factors
and chemokines in the BALF of mice treated with active rCARDS
toxin including G-CSF, KC, MCP-1, MIP-1a, and MIP-1b
(Figure 2 and Table 1). Both KC and MCP-1 had a more
prolonged secretion into the BALF, being elevated until at least
day 4 post-treatment (Figure 2B and C). Unlike most of the other
cytokines that exhibited peak expression at day 2 post-treatment
and then rapidly returned to baseline, 700 pmol CARDS toxin
was able to induce a dose-dependent and sustained expression of
IL-12p40 and KC that lasted until day 7 post-exposure (Figure 2
and Table 1). The patterns of cytokine expression detected by
ELISA (Figure 2) and Luminex (Table 1) were in good agreement
although the magnitude of the cytokine responses cannot be
directly compared since the data are from separate experiments.
The pattern of cytokine responses and the ability of mice to
respond to rCARDS toxin may not be reflective of the human
response to toxin exposure. While it is not currently possible to
directly test human responses to rCARDS toxin, we were able to
test the response of non-human primates (baboons). Clinically, the
baboons tolerated the procedures well and remained afebrile with
normal chest radiographs (not shown). The concentration of
cytokines in the BALF after treatment with active rCARDS or HI
rCARDS toxin was determined by Luminex assay using a
validated panel as described [31,32,33]. As shown in Table 2,
elevations in cytokine and chemokine concentrations were noted
in the active rCARDS toxin-treated animal at days 1 and 2, but
not in the control: G-CSF (40 fold), IL1Ra (10 fold), IL6 and IL8
(333 and 100 fold, respectively), MIP-1a (5 fold), and RANTES (9
fold) (Table 2). Overall, the responses in the baboon closely
mimicked those observed in the mouse suggesting a conserved
mechanism of immune activation by the CARDS toxin.
rCARDS toxin induces lymphocytic inflammation
Infection of mice with M. pneumoniae leads to dynamic
inflammatory changes in pulmonary histopathology [34]. Based
on observations with M. pneumoniae infections, it was important to
examine the histopathology that follows CARDS toxin exposure.
We treated mice IN once with 175 or 700 pmol active rCARDS or
HI toxin. On days 2, 4, 7, 14, and 37 post toxin, mice were
euthanized and the lungs prepared for routine hematoxylin and
eosin staining by fixation in 10% neutral buffered formalin (NBF)
prior to being embedded in paraffin, sectioned, and stained. No
histologic abnormalities were present in saline treated control
lungs, and heat-inactivated toxin treated lungs showed minimal
numbers of lymphocytes in peribronchiolar and perivascular sites
(Figure 3A and not shown).
Dramatically, lungs from mice treated with 43.7 pmol, 175
pmol or 700 pmol CARDS TX showed striking vacuolization of
bronchial and bronchiolar epithelium at the 2-day study period
Figure 1. Vacuolation activity of rCARDS toxin. A) SDS-PAGE analysis of the peak fractions of rCARDS toxin after both nickel (Ni) affinity resin
and polymixin columns reveals a single protein species of the appropriate size. B) HeLa cells treated with 700 pmol of HI toxin for 16 hrs serve as a
negative control for assessment of vacuolization by microscopy. C and D) HeLa cells treated with 175 and 700 pmol of rCARDS for 16 hrs, respectively,
exhibit a dose-dependent increase in numbers and sizes of vacuoles (small [175 pmol] and large [700 pmol] white arrows) relative to the negative
control cells. Also, note the cytotoxic effect of rCARDS (double black arrows).
doi:10.1371/journal.pone.0007562.g001
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4A). This finding mimicked previously reported changes in the
epithelium of baboon tracheal rings treated with CARDS toxin
[27] but is the first demonstration of the ability of rCARDS toxin
to induce vacuolization in vivo. In the lungs that received 175
pmol CARDS TX, scattered lymphocytes, but no neutrophils,
were evident in the septae and occasional airways and vessels at
days 2 and 4 (not shown). At day 7, patchy, small numbers of
lymphocytes were present, but at 14 days the lungs appeared near
normal (not shown).
The histopathological findings in the lungs treated with 700
pmol CARDS TX showed striking histopathological lesions that
were very similar to those we have reported in lungs inoculated
with live M. pneumoniae organisms. At 2 days post-inoculation with
700 pmol CARDS toxin, an intense inflammatory response was
evident focally in the walls of pulmonary vessels and airways,
alveolar spaces, and the interstitium (Figure 4A). The dominant
cell type was the neutrophil, but many small lymphocytes were
also present, especially around some vessels, probably venous, with
fewer in the edematous walls around airways and the accompa-
nying pulmonary artery branch. The pneumonitic exudates in
alveolar spaces contained numerous neutrophils (Figure 4A and B
circles). As noted above, the airways were lined by injured
respiratory epithelium that showed vacuolization, cytoplasmic
degenerative changes and cilial damage. At day 4, the striking
lesion was the multilayered collections of small lymphocytes that
encircled the pulmonary arteries and veins with small peribron-
chial/iolar accumulations (Figures 5, 6, and 7). Foci of pneumonia
were present, but the respiratory epithelium lacked the severe
vacuolization detected at day 2. The pronounced perivascular
infiltrates present four days after exposure to 700 pmol rCARDS
are similar to lesions observed during infection. For example,
lymphocytes are readily observed both perivascularly and tightly
attached to the endothelium adjacent to the infiltrates (Figure 7A
and B, arrows). At day 7, the lymphocytic infiltrates were more
extensively layered around vessels and bronchioles (Figure 6A and
B). Although a few lymphocytes had appeared more blastic at day
4, this change to larger cell size, more abundant cytoplasm and
enlarged nuclei with prominent nucleoli was particularly striking at
day 7. Foci of these reactive lymphocytes were embedded in the
Figure 2. Changes in cytokine/chemokine concentrations in BALF after exposure to active CARDS toxin. Mice were treated IN with 700
pmol of rCARDS toxin (solid bars) or 700 pmol of HI toxin (open bars) and concentrations of cytokines/chemokines in the BALF were determined by
ELISA. Baseline data are obtained from mice treated with saline for 2 days (stippled bars). A) Statistically significant (p,0.05) increase in IL-6 is
observed relative to baseline and HI toxin that declines by day 4. B) Statistically significant (p,0.05) increase in MCP-1 is observed relative to baseline
and HI toxin on days 2 and 4. C) Statistically significant (p,0.05) increase in KC is observed relative to baseline and HI toxin on days 2 and 4. D)
Statistically significant (p,0.05) increase in TNF-a is observed relative to baseline and HI toxin that declines by day 4. Data are representative of two
independent experiments with 5 to 10 mice/time point/treatment group. Data are presented as the average 6 the standard deviation.
doi:10.1371/journal.pone.0007562.g002
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the perivascular lymphoid aggregates were waning in number but
still numerous around vessels and occasional airways (Figure 6C).
At day 37, only scattered aggregates of perivascular lymphocytes
were evident (Figure 6D).
On days 4 and 7 post-treatment, quantitative scoring of the
lesions revealed statistically significant differences in the histolog-
ical scores of the animals treated with 700 pmol of rCARDS toxin
relative to the animals treated with an equivalent amount of heat-
inactivated toxin (Figure 8).
The lung of the mouse is anatomically different from that of
humans and other primates raising the possibility that the primate
lung may respond differently to rCARDS toxin exposure. To
investigate the pathological changes in primates, sections of
baboon trachea, right and left lower lobe bronchi, and distal
bronchi and bronchioles were obtained (Figure 9). Histopatholog-
ically, trachea and bronchi of the HI control showed focal
epithelial loss and scattered eosinophils secondary to the aggressive
lavage procedures (not shown). Distal bronchi and bronchioles
showed intact epithelium and no mural inflammation (Figure 9A),
with only scattered small collections of bronchus-associated
lymphoid tissue in some bronchiolar walls. In active toxin-treated
baboon specimens, the trachea, right and left main bronchi and
more distal bronchi showed extensive denudation of epithelium
and increased numbers of lymphocytes and scattered eosinophils
in the submucosa (not shown). A lymphocytic bronchiolitis was
identified in numerous bronchioles, and foci of alveolar edema
were present (Figure 9B). These data suggest that the CARDS
toxin is capable of eliciting a response in the baboon that is
consistent with what is observed in human M. pneumoniae infection
and in mouse models of both infection and intoxication.
Toxin mediated changes in airway function
The primary function of the lung as an organ of gas exchange
can be significantly impacted by both acute and chronic
inflammation. The robust changes in cytokine expression and
histopathology after rCARDS toxin treatment suggest that
CARDS toxin has the potential to induce significant immune
pathology in the lung. Changes in airway function can be a direct
result of inflammation, as is the case with the asthmatic lung, and
Table 1. Cytokine Levels in the Mouse Bronchial Alveolar Lavage Fluid after Exposure to CARDS Toxin.
700pmol CARDS
D a y 2 2 4 4771 4 1 4
Cytokine
a Baseline
b Active HI
c Active HI Active HI Active HI
IL-1a 260.8 3096175* 29649 10667 627 614 60.4 0.860.7 261.4
IL-1b 1360.2 123669* 23661 9 60.4 20612 1 611 9 611 2 60.4 1260.7
IL-6 360.8 49644* 6645 60.5 460.3 560.8 460.5 0.860.7 2.161.4
IL-12p40 660.5 105641* 9610 956105* 562.5 17697 666 635 61
IL-12p70 5621 1 63* 3632 612 612 612 615 615 61
IL-17 0.960.2 15610** 5687 682 622 621 61 0.660.3 0.560.5
G-CSF 660.1 5096444* 18618 30627 10621 0 60.9 8.560.1 660.1 660.1
KC 660.2 59633* 11674 3 631* 9624 2 640 12678 639 64
MIP-1a 860.7 2106110* 15626 17615 760.4 10611 4638 638 61
MIP-1b 1260.6 70658 18621 9 621 6 60.1 18621 6 60.4 1260.5 860.9
RANTES 460.1 66630* 8624 5 646 760.9 12657 613 60.8 460.2
175pmol CARDS
D a y 2 2 4 4771 4 1 4
Cytokine Baseline Active HI Active HI Active HI Active HI
IL-1a 260.8 7621 2 655 60.6 6616 635 622 60.9 361.4
IL-1b 1360.2 2060.9 23631 9 60.6 1960.5 16631 3 621 2 60.2 1260.7
IL-6 360.8 560.4 460.3 560.5 460.3 6624 60.5 2613 62
IL-12p40 660.5 9665 623 60.1 460.2 5626 60.3 2613 61
IL-12p70 5623 60.7 2612 612 624 625 614 617 64
IL-17 0.960.2 260.5 260.5 0.660.5 0.560.5 0.660.6 160.2 0.960.2 160.3
G-CSF 660.1 10611 1 619 60.5 960.2 7616 60.1 660.08 660.7
KC 660.2 9611 0 638 60.5 760.2 10626 60.5 8626 60.7
MIP-1a 860.7 6652 627 604 627 647 60.3 1260.7 861
MIP-1b 1260.6 1760.4 1660.1 1660.1 1660.1 15621 2 60.7 1260.7 1260.5
RANTES 460.1 8617 60.2 760.1 760.2 6624 614 60.1 460.1
aCytokines showing an increase over basal levels when animals are exposed to active CARDS toxin. Representative data from two independent assays with 5 to10 mice/
time point/treatment group each are presented. Data are reported as pg/ml and presented as the average 6 the standard deviation.
bBaseline measurements were obtained from 5 animals treated with saline for two days.
cHI toxin was boiled for one hour prior to use.
*p,0.05 comparing active toxin to baseline or a similar amount of HI toxin.
**p,0.05 comparing active toxin to baseline.
doi:10.1371/journal.pone.0007562.t001
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in airway function using unrestrained whole-body non-sedated
plethysmography as we and others have described previously
[11,13,14,15,16,35,36,37,38]. We chose this method because it
allows us to serially monitor the same animals over time, thus
giving us the advantage of following disease development and
resolution in the same cohorts of animals. Further, a rigorous
direct comparison of Penh versus invasive measurement of lung
resistance in mice was published (39). This direct comparison
found that for BALB/c mice the correlation coefficient was 0.809
between Penh and invasive measurement of lung resistance
(P,0.05).
BalbC/J mice were treated IN with 175 or 700 pmol rCARDS
toxin or carrier fluid, and then baseline AO and AHR were
determined on day 2. As shown in Figures 10A and B, 700 pmol
rCARDS toxin induced statistically significant (p,0.05) changes in
both AO and AHR two days after toxin exposure. There was no
difference in AO between animals treated with HI CARDS toxin
or carrier fluid (Figure 10C). Therefore, carrier fluid was used in
all subsequent studies. To determine the kinetics of the changes in
airway function, mice were treated with a single dose of 700-pmol
rCARDS toxin and then AO was monitored 2, 4, 7, 14, 21, 28,
and 37 days post treatment. rCARDS toxin induced a prolonged
statistically significant (p,0.05) change in AO that lasted 21 days
post-toxin treatment (Figure 10D). Altogether, these data indicate
that a single application of active rCARDS toxin is capable of
inducing prolonged AO and transient AHR.
Discussion
This study represents the first analysis of the interaction of
M. pneumoniae CARDS toxin with the immune system of an
experimental animal model. While many bacterial pathogens
produce toxins that modify the host response to infection, the
recently discovered CARDS toxin, in contrast to many bacterial
toxins, is unique in that it is both a vacuolating and ADP-
ribosylatingtoxin.Currently,itisnotclearhow ADP-ribosylation or
the phenotype of vacuolation correlates with the ability of the
CARDS toxin to induce inflammation. However, the data
presented in this study indicate that CARDS toxin is capable of
inducing pro-inflammatory cytokine expression in the lungs of mice
and baboons. In mice treated with a single dose of rCARDS toxin,
the toxin induces a transient pro-inflammatory response character-
ized by increased expression of IL-1, 6, 12p40, 17, and TNF-a as
well as a number of inflammatory chemokines. In the baboon, G-
CSF, IL-1ra, 6, 8, MIP-1a, RANTES, and IFN-c were readily
detectable after rCARDS toxin treatment. The pattern of pro-
Figure 3. Vacuolization of bronchiolar epithelium after CARDS toxin exposure. Two days after IN exposure to 43.7 pmol of active rCARDS
toxin or HI toxin, histological changes in lung specimens were evaluated. A) Bronchiolar epithelial cells appear normal in the HI toxin–treated lung.B )
Extensive vacuolization of the airway epithelium is evident in rCARDS toxin-treated lung. B=bronchiole. Hematoxylin and eosin, X 40 & 20 original
magnification, respectively.
doi:10.1371/journal.pone.0007562.g003
Table 2. Cytokine Levels in the Baboon Bronchial Alveolar
Lavage Fluid after Exposure to CARDS Toxin.
Cytokine
a Baseline
b Baseline HI
c Day 1
d Day1 HI
d Day 2
d Day 2 HI
d
IL-12p40 7 7 3 1.28 3 1
IL-17 10 10 7.4 10 2.5 10
IL-1ra 95 61 9.8 7 4 0.93
IL-6 6 6 333.6 14.7 320 1
IL-8 6 6 97.6 23 48 1
IFN-c 66 1 3 61 . 5 6
MCP-1 453 619 1.3 1.6 1.3 0.5
MIP-1a 69 6 4.8 23 3 2
RANTES 13 11 8.5 1.4 3.1 0.36
G-CSF 17 19 40.8 2.3 8.0 0.68
aCytokines expressed at days 1 and 2 after treatment with 700 pmol active
rCARDS toxin or 700 pmol heat inactivated toxin.
bBaseline values obtained in the pre-procedure BALF expressed as pg/ml.
cBaseline values obtained in the pre-procedure BALF for HI toxin expressed as
pg/ml.
dCytokine levels were determined by Luminex assay and are presented as fold
increases over baseline. No changes were detected in: M-CSF, IFN-a, IL-1b, IL-2,
IL-4, IL-5, IL-10, IL-18, MIP-1b,T N F - a, TNF-b.
doi:10.1371/journal.pone.0007562.t002
CARDS Tox Induced Inflammation
PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7562inflammatory cytokine expression in both mice and baboons is
remarkably similar to that observed during human pulmonary
infection with M. pneumoniae [3], including the prolonged expression
of IL-12p40 after rCARDS toxin exposure. The relatively high
levels of IL-12p40 but lower levels of IL-12p70 may suggest a
role for IL-23, but this remains to be investigated. Hardy and co-
workers have demonstrated that mice lacking IL-12 infected with
M. pneumoniae have less severe disease and rapidly resolve inflam-
matory changes in lung histology [15]. In contrast, treatment of
mice with rIL-12 during the acute phase of infection prolongs acute
disease, increasespro-inflammatorycytokine levels, and exacerbates
inflammatory pathology as well as changes in airway function [14].
rCARDS toxin appears to be capable of inducing several but not all
of the cytokines reported to be produced after M. pneumoniae
infection, which is predictable given the complexity of mycoplasma
antigens presented to the immune system during infection.
Clearly, exposure to rCARDS toxin not only increases pro-
inflammatory cytokine levels but also leads to profound changes in
Figure 4. Histological changes in lungs after exposure of mice to 700pmol of rCARDS toxin for two days. A) Epithelial vacuolization in
the terminal bronchiole (B), ulceration of the epithelium, and neutrophilic exudates are evident at the respiratory bronchiolar level (arrow). The
surrounding alveolar spaces contain exudates of neutrophils and rare alveolar macrophages (circles). Whereas the pulmonary artery (A) is enclosed by
edema and scattered inflammatory cells, the pulmonary venule (v) shows a mixed perivascular infiltrate of mononuclear and a few acute
inflammatory cells. B) is a 4-fold magnification of the area enclosed within the circle indicated on Panel A. Hematoxylin and eosin, X 10 & 40 original
magnification, respectively.
doi:10.1371/journal.pone.0007562.g004
Figure 5. Lymphocytic inflammation four days after treatment with 700 pmol of rCARDS toxin. A) Focal collections of neutrophils in
alveolar spaces are evident. The epithelium of the bronchiole lacks the vacuolization lesion, and the pulmonary artery (A) and vein (V) show
multilayered mononuclear cells (circle) with predominantly small lymphocytes and rare neutrophils. B) is a 2-fold magnification of Panel A.
Hematoxylin and eosin, X 20 & 40 original magnification, respectively.
doi:10.1371/journal.pone.0007562.g005
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ADP-ribosylating and vacuolating toxin that is capable of inducing
vacuoles in both cell and organ cultures (27). Here we
demonstrated that early after a single exposure to rCARDS toxin,
frequent and consistent vacuolization of the bronchiolar epithe-
lium in vivo occurs that resolves by day 4, which corroborates our
initial studies in tissue and organ culture [27]. Interestingly, the
kinetics of the resolution of the vacuolization is consistent with
rapid regeneration of bronchiolar epithelium.
The CARDS toxin-mediated inflammatory infiltrates are very
similar to those observed during M. pneumoniae infection, and the
perivascular lesions suggest a hematological origin (Figure 7).
rCARDS toxin eventually induces a robust peribronchial
inflammation evident starting at day 4 post exposure. How
specific cytokines and chemokines actually contribute to the
development of these inflammatory infiltrates remains to be
identified, but previous studies suggest that IL-12 might play a
significant role [14,15]. The cellular infiltrates are unusual in that
they are predominantly lymphocytic in nature and increase in
severity over a seven-day period in a dose-dependent manner
following a single exposure to toxin. The presence of lymphoblasts
after toxin exposure is uncommon during the host response to
most bacterial toxins, and it is unclear what the significance of this
finding is. However, it indicates a complex and interdependent
relationship between M. pneumoniae CARDS toxin and the immune
system. For example, the same lymphocytic aspect of the
histopathology is observed following both M. pneumoniae infection
and intoxication, suggesting a role for toxin during infection.
Pathophysiologically, exposure to CARDS toxin and the
associated inflammatory responses in the lungs could account for
the changes observed in pulmonary function after infection.
Mouse models of chronic respiratory infection with M. pneumoniae
Figure 6. Peak inflammatory lesions and resolution of cellular infiltration 7 to 37 days after treatment with 700 pmol rCARDS toxin.
A) 7 days post-toxin treatment, focal pneumonitic exudates are evident in alveoli, but the striking lesions at this time point are the condensed
perivascular and fewer peribronchiolar lymphocytic infiltrates. B) The rectangular area in Panel A is a collection of lymphoblasts present amongst the
small lymphocytes (magnified 6-fold). C) 14 days post-treatment, the perivascular and peribronchial/iolar lymphoid infiltrates are much fewer in
distribution and number. D) 37 days post-toxin treatment perivascular and peribronchial lesions are rare but still present in rCARDS toxin-treated
lungs. artery=A, B=bronchiole, V=vein. Hematoxylin and eosin, X 10, 60, 10, and 10 original magnification, respectively.
doi:10.1371/journal.pone.0007562.g006
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chronically infected animals develop alteration in lung compli-
ance, functional AO and AHR, as well as histological evidence for
airway inflammation accompanied by fibrosis [10,11,12,40]. Here
we report that mice exposed to a single dose of rCARDS toxin
develop statistically significant prolonged AO over 21 days and
AHR at day 2-post exposure. The fact that AHR waned prior to
resolution of AO indicates that AHR requires a sustained exposure
to toxin, which would be typical of the infectious process.
Prolonged AHR similar to what is observed during infection
may also have been observed with a continuous toxin challenge.
These data suggest that a single exposure to CARDS toxin is
sufficient to cause significant changes in histopathology and airway
function in mice that may be clinically relevant to a range of
M. pneumoniae-associated sequelae.
Mycoplasma pneumoniae has been implicated as a causative agent
or an exacerbating factor in a number of acute and chronic
airway-associated inflammatory conditions ranging from tracheo-
bronchitis and community acquired pneumonia to asthma and
COPD in both children and adults [3,5,6,7,8,41,42]. In adults, M.
pneumoniae has been detected in the airways of chronic, stable
asthmatics using PCR with significantly greater frequency than in
non-asthmatic control subjects [6,43]. In a randomized, double
blind, placebo-controlled trial of prolonged (6 week) clarithromy-
cin therapy in 55 adult subjects with chronic, stable asthma [44]
M. pneumoniae was detected by PCR in the airways of 23 of the 55
asthmatics. Prolonged clarithromycin therapy resulted in a
significant improvement in pulmonary function (FEV1) only in
the PCR-positive asthmatics (p=0.05) and was without effect
in the PCR-negative asthmatics (p=0.85), directly linking
M. pneumoniae and mycoplasma products to airway dysfunction.
A conclusive causal link between M. pneumoniae infection and
reactive airway disease is lacking but based on the ability of
rCARDS toxin to induce robust inflammation and both AO and
AHR in mice, it would be reasonable to predict that CARDS toxin
would elicit similar responses in humans. Further, the improve-
ment in airway function after antibiotic treatment (42) suggests
that a virulence factor sensitive to protein synthesis inhibitors
might play a role in the pathogenesis of disease. CARDS toxin is a
likely candidate based on the in vivo effects of rCARDS toxin
reported in this study and the fact that the magnitude of CARDS
toxin expression by M. pneumoniae is markedly increased in vivo
using the mouse model of infection relative to toxin expression
during broth culture (T.R. Kannan et al Submitted).
Currently, there is no reliable way to estimate the total amount
of CARDS toxin produced in vivo during M. pneumoniae infection.
Therefore, it is difficult to make direct comparisons between
treatment with rCARDS toxin and toxin produced during
infection although the host response to rCARDS exposure or
infection shares similarities (3,27). During infection many factors
can lead to an inflammatory response, and it is unlikely that a
single M. pneumoniae product accounts for the overall cytokine
responses, the corresponding lymphocytic inflammation, as well
as changes in airway function. During infection, the airway-
associated histopathology and airway dysfunction, which we
observed after rCARDS treatment alone, can be further
amplified by other immuno-reactive mycoplasma products
present at the site of infection. However, the results of this study
suggest that the CARDS toxin is sufficient to induce major
inflammatory phenotypes associated with M. pneumoniae infection
in rodents and primates. These data support the concept that the
CARDS toxin plays a fundamentally important role in the
pathogenesis of M. pneumoniae infection and the sequelae
associated with infection. Clinically, it is likely that CARDS
toxin is a significant cause of human morbidity associated with
M. pneumoniae infection.
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Figure 7. Mouse perivascular lesions evident in the lung 4 days after M. pneumoniae infection. A) Low power micrograph shows scattered
alveolar exudates (circle) proximal to a venule (v) with a mural cellular infiltrate of small mononuclear cells, predominately small lymphocytes. B)i sa
4-fold magnification of Panel A) showing that the vessel wall is infiltrated with multilayered small lymphocytes. The endothelium is edematous, and
adherent inflammatory cells are occasionally evident (arrow). Compare this histopathology to similar lesions induced by active rCARDS toxin
presented in Figure 5A & B. Hematoxylin and eosin, original magnifications 106and 406respectively.
doi:10.1371/journal.pone.0007562.g007
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PLoS ONE | www.plosone.org 10 October 2009 | Volume 4 | Issue 10 | e7562Figure 9. rCARDS toxin induction of inflammatory changes in primate lungs. 700 pmol of active or HI CARDS toxin were introduced directly
into the baboon lung. A) Normal appearing bronchioles (B)areevidentin the HI toxintreated lung. B) Intrabronchial instillationof CARDS toxin results in
a lymphocytic bronchiolitis and an early perivascular component (circle). artery=A. Hematoxylin and eosin, X10 original magnification, respectively.
doi:10.1371/journal.pone.0007562.g009
Figure 8. Quantifiable inflammatory histopathology observed in rCARDS toxin-treated mice. Histopathology was scored in a blinded
fashion, and sections were given a numerical score as described in the Materials and Methods. The most significant changes were observed in animals
treated with 700 pmol of rCARDS on days 4 and 7 post-treatment. Data represents the average 6 standard deviation with 8 to10 mice/time point/
treatment group. Data sets were analyzed for statistical significance by comparing animals treated with the indicated amount of toxin to the
corresponding group of animals treated with HI toxin *=p,0.05, **=p,0.005.
doi:10.1371/journal.pone.0007562.g008
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PLoS ONE | www.plosone.org 11 October 2009 | Volume 4 | Issue 10 | e7562Figure 10. Airway obstruction and airway hyperreactivity in mice after pulmonary exposure to rCARDS toxin. A) Baseline AO is
presented in response to different amounts of rCARDS toxin 2 days post-treatment (*=p,0.05) relative to carrier fluid (CF). B) Methacholine
responsive AHR is observed 2 days after treatment with the indicated amount of rCARDS toxin (*=p,0.05) relative to CF. C) Lack of AO is observed in
response to 700 pmol of HI toxin or CF. D) AO remains detectable over a 37 day time course with mice treated with 700 pmol of rCARDS or CF.
*=p,0.05. Data are presented as the average 6 standard deviation with 5 to 10 BALB/c mice/time point/treatment group.
doi:10.1371/journal.pone.0007562.g010
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